Workflow
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
再生元再生元(US:REGN) ZACKS·2025-08-02 00:11

Key Takeaways REGN posted Q2 EPS of 12.89,up1212.89, up 12% year over year and beating the 8.03 consensus estimate.Q2 revenues rose 4% to 3.7B,drivenbyEyleaHDdemandandhigherDupixentcollaborationprofits.BothLibtayoandEyleaHDsalestoppedestimates;Dupixentsalesrose223.7B, driven by Eylea HD demand and higher Dupixent collaboration profits.Both Libtayo and Eylea HD sales topped estimates; Dupixent sales rose 22% to 4.3B globally.Regeneron Pharmaceuticals, Inc. ((REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of 12.89,whichcomfortablybeattheZacksConsensusEstimateof12.89, which comfortably beat the Zacks Consensus Estimate of 8.03. The bottom line increased 12% from $11. ...